US 2017/0304364 A1Published application

Nk-92 cells in combination therapy with cancer drugs

AssigneeNantKwest, Inc.

InventorsTien Lee, Hans G. Klingemann, Barry J. Simon

Life of this patent

Estimating the term…

Abstract

This disclosure is directed to compositions and methods for treating cancer using combination therapies of NK-92 cells with cancer drugs (e.g. thalidomide, cisplatin, and paclitaxel).

Claims20

Dependent claims

-27. (canceled)

A method of treating a subject having a cancer, comprising administering to the subject an effective amount of at least one cancer drug and at least one NK-92 cell.

Dependencies are inferred from the claim text.

Facts

Application: 15/526,157Filed 25 Mar 2016
Priority: 27 Mar 2015
Published: 26 Oct 2017
Term ends: Not estimatedThe source records don’t support an estimate.

Classification17 codes

A61K 31/454
Containing further heterocyclic ring systems: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/337
Having oxygen as the only ring hetero atom, e.g. fungichromin: having four-membered rings, e.g. taxol
A61K 35/13
Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically…:…
A61K 38/09
Peptides having 5 to 11 amino acids: luteinising hormone-releasing hormone [LHRH] , i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides

Family

Application62/139,330Us provisional application · filed 27 Mar 2015
US 2017/0304364 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results